Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

(2021) Shilong Yang et al.   LANCET INFECTIOUS DISEASES

SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients

(2021) Yao Deng et al.   Cellular & Molecular Immunology

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

(2021) Amy Flaxman et al.   LANCET

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

(2021) Ann R. Falsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

(2021) David Hillus et al.   Lancet Respiratory Medicine

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

(2021) Shuo Feng et al.   NATURE MEDICINE